Axsome Therapeutics, Inc. (AXSM) vs Caris Life Sciences, Inc. (CAI)
A side-by-side comparison of Axsome Therapeutics, Inc. and Caris Life Sciences, Inc. across valuation, profitability, dividends, and growth — built entirely from reported fundamentals, as of October 6, 2026. Differences are shown without an overall score or investment verdict.
AXSM
Axsome Therapeutics, Inc.
$177.08HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
CAI
Caris Life Sciences, Inc.
$30.39HealthcareDelayed quote: Oct 5, 2026, 4:00 PM EDT
Total return — AXSM vs CAI
growth of $100 · dividends reinvested · last 1yAXSM +74.3% (+74.3%/yr)CAI +8.5% (+8.5%/yr)AXSM compounded faster over this window
AXSM CAI
AXSM vs CAI: by the numbers
- •AXSM is the larger company ($9.11B vs $8.59B market cap).
- •CAI is profitable (10.62% net margin) while AXSM runs a net loss (-24.68%).
Metrics side by side
Valuation
| Metric | AXSM | CAI |
|---|---|---|
| P/E ratio | N/A | 84.91 |
| Forward P/E | N/A | 261.92 |
| P/S ratio | 11.73 | 8.68 |
| P/B ratio | 109.39 | 14.52 |
| EV / EBITDA | N/A | 47.99 |
| FCF yield | N/A | 1.71% |
Profitability
| Metric | AXSM | CAI |
|---|---|---|
| Gross margin | 93.24% | 69.66% |
| Operating margin | -24.28% | 5.56% |
| Net margin | -24.68% | 10.62% |
| ROE | -230.05% | 17.77% |
| ROIC | -50.82% | 14.76% |
Growth (annualized)
| Metric | AXSM | CAI |
|---|---|---|
| Revenue CAGR (5Y) | N/A | 26.15% |
| Total return CAGR (5Y) | 41.40% | N/A |
Frequently asked
- Is AXSM or CAI more profitable?
- CAI runs the higher net margin — AXSM at -24.68% versus CAI at 10.62%.
Go deeper
Dig into the metrics
Caris Life Sciences P/E ratioAxsome Therapeutics ROECaris Life Sciences ROEAxsome Therapeutics operating marginCaris Life Sciences operating marginAxsome Therapeutics revenue growthCaris Life Sciences revenue growthAxsome Therapeutics free cash flowCaris Life Sciences free cash flow
Axsome Therapeutics & Caris Life Sciences appear in these rankings
Figures are sourced from reported fundamentals and the latest end-of-day price. This comparison is informational only and is not investment advice. Past performance does not predict future results. See our methodology. Compiled by TGMCharts Research · data verified October 6, 2026.